Drugs / Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06066359 | Nov 2023 → Aug 2026 overdue | refractory plasma cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06066359 ↗ |
| Modality | Cell therapy | “Cord Blood-derived Natural Killer Cells” NCT06066359 ↗ |
| Route | Intravenous | “Given by (IV) vein” NCT06066359 ↗ |